Arcellx, Inc. financial data

Symbol
ACLX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
800 Bridge Parkway, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 537 % +56.9%
Debt-to-equity 59 % -43%
Return On Equity -8.28 % +82.9%
Return On Assets -5.21 % +78.1%
Operating Margin -44.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.1M shares +11.1%
Common Stock, Shares, Outstanding 54M shares +10.9%
Entity Public Float 1.3B USD +187%
Common Stock, Value, Issued 53K USD +10.4%
Weighted Average Number of Shares Outstanding, Basic 53.8M shares +11.3%
Weighted Average Number of Shares Outstanding, Diluted 53.8M shares +11.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 156M USD +74%
Research and Development Expense 141M USD +7.8%
General and Administrative Expense 84M USD +37.6%
Operating Income (Loss) -69.4M USD +52.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.2M USD +69.7%
Income Tax Expense (Benefit) 1.19M USD +2793%
Net Income (Loss) Attributable to Parent -40.4M USD +68.8%
Earnings Per Share, Basic -0.71 USD/shares +75.3%
Earnings Per Share, Diluted -0.71 USD/shares +75.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 162M USD +28.3%
Marketable Securities, Current 412M USD +31.5%
Cash, Cash Equivalents, and Short-term Investments 483M USD
Assets, Current 587M USD +19.5%
Property, Plant and Equipment, Net 47.5M USD +25.7%
Operating Lease, Right-of-Use Asset 23.9M USD -17.9%
Assets 765M USD +24.5%
Accounts Payable, Current 5.99M USD -16.6%
Accrued Liabilities, Current 43M USD +154%
Contract with Customer, Liability, Current 69.9M USD -25.8%
Liabilities, Current 137M USD -20.9%
Contract with Customer, Liability, Noncurrent 82.6M USD -31.8%
Operating Lease, Liability, Noncurrent 47.2M USD -1.83%
Other Liabilities, Noncurrent 15M USD
Liabilities 282M USD -19%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.9M USD
Retained Earnings (Accumulated Deficit) -450M USD -9.88%
Stockholders' Equity Attributable to Parent 483M USD +81.5%
Liabilities and Equity 765M USD +24.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.9M USD -118%
Net Cash Provided by (Used in) Financing Activities -2.99M USD -103%
Net Cash Provided by (Used in) Investing Activities -207M USD -210%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 54M shares +10.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -242M USD -215%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 164M USD +25.5%
Deferred Tax Assets, Valuation Allowance 91.8M USD +2.19%
Deferred Tax Assets, Gross 104M USD +5.76%
Operating Lease, Liability 58.3M USD +70.6%
Payments to Acquire Property, Plant, and Equipment 6.43M USD +556%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.5M USD +70.2%
Lessee, Operating Lease, Liability, to be Paid 95.5M USD +2.48%
Property, Plant and Equipment, Gross 48M USD +227%
Operating Lease, Liability, Current 7.25M USD +10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.5M USD +40.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.84M USD +160%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 35.3M USD -8.83%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.75M USD +7.23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 3.45M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.01M USD +7.12%
Operating Lease, Payments 757K USD +267%
Additional Paid in Capital 931M USD +37.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 826K USD +91.2%
Deferred Tax Assets, Net of Valuation Allowance 11.7M USD +45.7%
Share-based Payment Arrangement, Expense 41.8M USD +94%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%